|
Draft Genetic Test Review Cystic
Fibrosis DISORDER/SETTINGQuestion 1: What is the specific clinical disorder to be studied?Question 2: What are the clinical findings defining this disorder? Question 3: What is the clinical setting in which the test is to be performed? Question 4: What DNA test(s) are associated with this disorder? Question 5: Are preliminary screening questions employed? Question 6: Is it a stand-alone test or is it one of a series of tests? Question 7: If it is part of a series of screening tests, are all tests performed in all instances (parallel) or are only some tests performed on the basis of other results (series)? DISORDER/SETTING
Question 1:
What is the specific clinical disorder to be studied?
The specific clinical disorder is cystic
fibrosis. Nearly all
individuals with cystic fibrosis have some degree of progressive lung
disease with abnormal chest x-rays, abnormal pulmonary function tests,
and abnormal sputum. The
natural history and variability of presentation is described in more
detail in later sections (Question 26).
A core panel of 25 mutations (Question 4, Table 1-1) is
recommended to be used for screening by the American College of Medical
Genetics and the American College of Obstetricians and Gynecologists.
All combinations of those mutations can be associated with severe
disease. One of the
mutations (R117H), however, often is not usually associated with this
disorder, and additional testing is necessary.
Another mutation (I148T) also seems to be of low penetrance, but
it is not yet known how to properly interpret this mutation.
More information about the genotype/phenotype relationship can be
found in later sections (Question 20 and 24).
Social context of cystic fibrosis carrier testing Evaluation
of prenatal screening for cystic fibrosis must take into account the
social context in which testing is done.
The carrier state itself has no medical implications and such
testing is done solely to assist in reproductive decision-making in a
variety of ways. Men and
women who know themselves to be carriers before marriage could reduce
their risk of having children with cystic fibrosis by deliberating
choosing marriage partners who are not known to be carriers of a
mutation. When both spouses
in a marriage are known to be carriers, the couple could choose not to
have children, adopt, use donor sperm (from a donor whose cystic
fibrosis carrier testing is negative), or consider pre-implantation
genetic testing. In
practice, however, most individuals show limited interest in cystic
fibrosis carrier testing prior to a confirmed pregnancy. Current protocols promote cystic fibrosis carrier testing in
the United States during pregnancy.
In this clinical setting, the primary purpose is to determine the
likelihood that the fetus is affected with cystic fibrosis.
This context has several ethical, legal and social implications.
First, careful attention must be given to the manner in which
carrier testing is offered as part of prenatal care.
It is important for couples considering prenatal screening to
understand that the purpose of the test is to determine the likelihood
that fetus is affected. If
both parents are found to be carriers, they will be offered prenatal
diagnosis. Prenatal
diagnosis provides parents the opportunity to consider termination of
the pregnancy if the fetus is found to have cystic fibrosis.
Without careful patient education about these issues, the offer
of screening could appear to be similar to other tests routinely offered
during pregnancy (e.g., blood glucose, blood pressure or pH) and thus
could be misconstrued as a test intended to help ensure a healthy
pregnancy outcome. Prenatal
screening for cystic fibrosis is optional in a way that most other
routine prenatal tests are not. Tests
to determine Rh status, for example, would be highly recommended, to
provide the obstetrician with the opportunity to take action if an Rh
incompatibility is found. By contrast, prenatal screening for cystic fibrosis and any
resulting prenatal diagnosis procedures, are optional interventions, to
be pursued only if the couple is informed and interested. Couples
may differ in their interest in prenatal testing, and in the value they
place on prenatal diagnostic information.
From the couple’s perspective, a prenatal diagnosis of cystic
fibrosis could have two potential values.
For some, the information allows them to prepare for the birth of
an affected child. For
others, the prenatal diagnosis of cystic fibrosis creates the
opportunity to terminate the pregnancy, in order to avoid the birth of
an affected child. Because
prenatal diagnosis does not currently lead to any medical treatment
(i.e., there are no in utero
treatments to prevent or ameliorate the clinical complications) couples
need to be fully informed about the potential outcomes of testing before
initiating the testing process. Prenatal
screening for cystic fibrosis and subsequent prenatal diagnosis fall
into a subset of medical tests that are performed for personal or social
purposes. Although the
interventions associated with a screen positive couple (prenatal
diagnosis; termination of an affected pregnancy) are considered medical
actions, the rationale for doing them is based in personal (family)
values, not in medical judgment. Prenatal
screening for cystic fibrosis results in a measurable outcome change
only if a pregnancy is terminated to avoid the birth of an affected
child. In our society, the
dominant ethical perspective related to this decision is that
reproductive decisions are private matters determined by the autonomous
choices of parents. This
moral framework dictates that prenatal screening for cystic fibrosis be
offered, but not recommended. Parental
decisions regarding whether or not to pursue carrier testing, prenatal
diagnosis, and pregnancy determination must be respected.
The emphasis of traditional genetic counseling on non-directive
modes of counseling reflects this perspective. Studies
of genetic counseling, and of medical decision-making in general, point
to difficulties in implementing the goal of non-directive counseling
particularly in a time limited setting.
Empiric observations in genetic counseling settings, for example,
suggest that genetic counselors may frequently make directive statements
in the course of counseling and/or patients may interpret offering a
test with recommending the test. Non-directiveness
may be more difficult to maintain in a routine obstetric practice
setting, where prenatal screening for cystic fibrosis is now recommended
to be offered to all pregnant women, than in a genetics clinic.
This is because the time for counseling is likely to be more
constrained and because the test is offered in the context of many other
prenatal tests. Thus, careful attention needs to be taken to maintaining the
ethical standard of informing
couples of the opportunity for carrier testing, rather than recommending a particular course of action.
Another
ethical concern is financial and medical access to pregnancy
termination. Health plans
differ in their coverage of mid-trimester pregnancy terminations, and
the availability of facilities providing this procedure varies
significantly in different locations.
For some couples at risk to have an affected child, this reality
may limit their choices and they should be made aware of this
possibility prior to consenting to the first stages of the testing
process. Individuals
found to be carriers will be encouraged to share this information with
their extended family. The
reactions of family members can be quite variable and unpredictable.
In the case where both members of a couple are carriers and they
are faced with decisions about prenatal testing and termination, caution
should be advised in when and how to share their test results with
family members and their support system. The
types of decisions couples may have to make during the process of
prenatal screening for cystic fibrosis can be quite complex. Information should be provided in multiple formats and on
multiple occasions to increase the likelihood that couples will have an
opportunity to make an informed decision.
Gaps in Knowledge
DISORDER/SETTING
Question 2: What are the clinical findings defining this disorder? Cystic
fibrosis is associated with major health problems and reduced life
expectancy. It is one of
the most common recessively inherited serious single gene disorders in
non-Hispanic Caucasians. In
that population group, about 1 in 25 (4%) are carriers, and the birth
prevalence of cystic fibrosis is about 1 in 2500.
The exocrine glands of affected individuals produce abnormally
thick secretions of mucus. This
abnormal mucus leads to a wide variety of progressive respiratory and
gastrointestinal problems, and impaired fertility in males.
Cystic fibrosis does not affect the sexual functioning of either
men or women. The long-term
prognosis has improved substantially during the past quarter century due
to more effective treatment, coupled with the availability of
centralized cystic fibrosis management units.
Over 90% of affected infants now survive beyond 1 year, and the
current median age of death has increased to about 30 years (Cunningham
and Taussig, 1999). There
is considerable variability in the rate of disease progression and
extent of pancreatic involvement, but nearly all homozygous individuals
develop serious clinical manifestations at some point.
The median predicted survival for individuals with cystic
fibrosis is 32.2 years (CF Foundation Registry Annual Report, 2000).
Treatment is presently directed at slowing the progress of the
disease. Gene therapy
offers promise for the future, but has not yet been successfully
accomplished. For a more
in-depth description of the cystic fibrosis phenotype, see Question 26. Question 3:
What is the clinical setting in which the test is to be
performed? In the prenatal setting, pregnant women and their
partners are the target group to be offered prenatal screening for
cystic fibrosis. This is
accomplished by identifying couples in whom both partners are carriers
of a cystic fibrosis mutation (carrier testing).
Such screening is offered in the physician office or clinic, as
part of prenatal care. Information
about cystic fibrosis screening is provided as early in pregnancy as
possible, preferably at, or before, the first visit (e.g., in a brochure
mailed before the initial prenatal care appointment).
For those who opt to be tested, samples are obtained and
processed promptly.
Although targeted in the first trimester, testing
can practically be offered as late as 20 weeks.
After that time, the options available to the parents may be
limited to preparing for management of an affected child.
Carrier couples who are identified are offered genetic counseling
and diagnostic testing of the fetus. Question
4: What DNA test(s) are
associated with this disorder? Background The
cystic fibrosis gene is located on the long arm of chromosome 7.
It spans some 230 kb of genomic DNA and contains 27 exons.
The gene product, the cystic fibrosis transmembrane conductance
regulator (CFTR), is expressed in exocrine glands of those tissues primarily
involved in the disease process, such as pancreas, nasal polyps, lung,
colon, sweat glands, placenta, liver, and parotid gland. It is a protein with a calculated molecular mass of 170,000,
showing strong homology with a class of ATP-dependent membrane transport
proteins (Kerem et al., 1989;
Riordan et al., 1989; Rommens et
al., 1989). Tracking the cystic fibrosis gene through protein assays is
impractical, because CFTR is
not expressed in accessible tissues such as red or white blood cells. To
date, over 900 different disease-causing mutations have been found in
this gene, and these vary in frequency according to geographical and
ethnic background (Brock, 2000). Many
mutations are extremely rare and have been found in one or a handful of
patients. The predominant
mutant allele at the CF locus is a three base-pair deletion in exon 10,
which removes a phenylalanine residue at position 508 of the 1480 amino
acid sequence of CFTR. This allele,
known as delF508 (F is the single letter code for phenylalanine), makes
up 50 to 90 percent of mutations in Caucasian populations (The Cystic
Fibrosis Genetic Analysis Consortium, 1990; Schwarz et
al., 1995). A different
mutation is the main cause of cystic fibrosis in Ashkenazi Jews.
Half of Ashkenazi Jewish carriers of cystic fibrosis have the
W1282X mutation (rarely found in non-Jewish carriers), whereas less than
one-third have the delF508 mutation.
In other populations, no single mutation accounts for a dominant
proportion. Laboratory
Tests It
is possible to detect both normal and mutant cystic fibrosis alleles in
any tissue sample which contains nucleated cells; in practice, this
means any tissue with the exception of mature red blood cells. Screening can be successfully done using either white blood
cells (Mennie et al., 1992;
Schwartz et al., 1993; Jung et al., 1994; Brambati et al.,
1996; Brock 1996; Cuckle et al.,
1996; Loader et al., 1996;
Witt et al., 1996; Eng et al., 1997) or buccal samples (Mennie et al., 1992; Harris et al.,
1993; Miedzybrodzka et al.,
1995; Brambati et al., 1996;
Brock 1996; Cuckle et al.,
1996; Harris et
al., 1996; Hartley et al.,
1997; Grody et al., 1997).
Blood samples (obtained by venipuncture) serve as a highly
reliable source for DNA and can be readily obtained in many health care
settings. The method of
collecting buccal cells by brush, “scoop” or mouthwash is
inexpensive and is well suited to collecting samples in primary care
settings or at home (Harris et al.,
1993; Livingstone 1994; Miedzybrodzka et
al., 1995; Wald et al.,
1995; Brock 1996; Doherty et al.,
1996; Harris et al., 1996; Hartley et al.,
1997; Bradley et al., 1998),
which may have advantages for aspects of the informed consent process
and for the ability to obtain simultaneous samples from both parents.
Buccal samples are stable when shipped at ambient temperature,
and testing has been successfully performed on buccal lysates stored
frozen for 3-4 years (Haddow et
al., 1999). Buccal
sample failure rates are generally 1% or less; results can nearly always
be obtained from blood samples. When
repeat samples are needed, they can nearly always be obtained.
Blood spots on filter paper cards have also been used as a
sampling method (Clayton et al.,
1995), but details of performance have not been reported. Of
the wide variety of testing methodologies available, most screening
trials have chosen forward dot-blot, reverse dot-blot, or amplification
refractory mutation system (ARMS™)
technologies. All appear
reliable, require only a small capital investment, support a reasonable
throughput of samples, can test either purified DNA or buccal lysates,
and require only a moderate level of technical skill.
Current estimates of unit reagent costs are about $30 to $50 per
test. In the United States,
however, no kits have been approved by the FDA for cystic fibrosis
testing, and none is known to be under review.
Laboratories offering such testing will likely come under
regulations for ‘home brew’ or, possibly, analyte specific reagents.
More automated methodologies are being developed; these may
improve capacity and throughput and reduce some costs (e.g., less
technologist time), but may require significant capital investment.
Examples include: ARMS™, fluorescent assay (Zeneca Diagnostics,
Cheshire, England), automation of reverse dot-blot strips (Linear Array
CF-31 from Roche Molecular Systems, Alameda, CA), INNO-LiPA CFTR29 (Innogenetics,
Alpharetta, GA), and PCR-OLA, a polymerase chain reaction followed by an
oligonucleotide ligation assay and a sequence coded separation (PE
Biosystems, Foster City, CA). The
American College of Obstetricians and Gynecologists/American College of
Medical Genetics (ACOG/ACMG) Task Force has recommended that prenatal
screening utilize all DNA mutations which occur in 0.1 percent or more
of the affected pan-ethnic American population (www.faseb.org/genetics/acmg/pol-32.htm).
The 25 mutations in that category are listed in Table 1-1.
A discussion about mutational panels that contain fewer (or more)
than the 25 suggested mutations is provided later, as part of the review
of mutation frequencies in specific racial/ethnic groups (Question 18). Table 1-1. Recommended
Core Mutation Panel for General Population Cystic Fibrosis
*Benign
Variants. This test
distinguishes between a cystic fibrosis mutation and these benign
variants. I506V, I507V, and
delF508C are performed only as reflex tests for unexpected homozygosity
for delF508 and/or delI507. **5T
in cis can modify R117H phenotype or alone can contribute to congenital
bilateral absence of vas deferens (CBAVD); 5T analysis is performed only
as a reflex test for R117H positives. *Table
taken directly from Grody et al.,
2001. Question
5: Are preliminary
screening questions employed? The
pros and cons of using an inquiry about racial/ethnic heritage as an
initial screening test were discussed extensively at a working
conference in 1998 that dealt with issues in implementing prenatal
screening for cystic fibrosis (Haddow et
al., 1999a; Haddow et al.,
1999b), as well as in a follow-up workshop to the NIH Consensus
Development Conference on Cystic Fibrosis (Mennuti and Press, 1998).
Both the population prevalence of cystic fibrosis and the
frequency of identifiable mutations vary greatly, depending upon race
and ethnicity (NIH Consensus Development Conference Statement.
Genetic Testing for Cystic Fibrosis).
Ashkenazi Jewish and other non-Hispanic Caucasian populations
have the highest prevalences, followed by Hispanic, African American and
Asian American populations. Cystic
fibrosis testing has the highest detection rate in Ashkenazi Jews,
followed closely by other non-Hispanic Caucasians.
Lower rates are found for African Americans, Hispanics and Asian
Americans. Given
this wide variation in cystic fibrosis prevalence (Question 21) and
mutation mix between populations (Question 18), it is most effective to
offer prenatal cystic fibrosis screening to couples who are Caucasian
and of European or Ashkenazi Jewish descent, and who are planning a
pregnancy or who are seeking prenatal care during the first or early
second trimester. Cystic
fibrosis screening could also be made available to racial and ethnic
groups that are at lower risk. These
couples could be provided with materials that make clear their risk for
having a child with cystic fibrosis and the sensitivity and specificity
of the available tests. The
limitations of prenatal screening in their racial/ethnic group should be
addressed and, if they understand this information and request testing,
it should be provided. One
way to understand the impact of population prevalence and percentage of
identifiable mutations is to determine the number of couples who need to
be screened per case detected. It
would be necessary to screen 3,500 non-Hispanic Caucasian couples to
identify one case of cystic fibrosis [population prevalence divided by
the product of the proportion of identifiable mutations in the two
partners, or [2,500 / (0.85)2] (Holmes et
al., 1998). For
Ashkenazi Jewish, Hispanic, African American, and Asian American
populations, one case would be identified for every 2,800, 24,000,
27,000 and 333,000 couples screened, respectively (Haddow et
al., 1999). Answers to a question about racial/ethnic heritage in a
screening setting have proven useful in distinguishing between these
various levels of risk, even though it is sometimes difficult to make
these assignments (Question 23). In
order to implement this approach, two strategies might be considered:
·
Prenatal
screening for cystic fibrosis might include a preliminary screening
question about racial/ethnic heritage, as is now the accepted practice
for some other genetic disorders, such as Tay-Sachs disease.
Only non-Hispanic Caucasians and Ashkenazi Jewish individuals
would be offered screening. Such
a strategy might be controversial.
·
Educational
materials would make clear to women and couples the prevalence and
screening performance in various racial/ethnic groups.
Among those low risk groups that have poor screening performance,
it is likely that many will decline (Loder et
al., 1996). Question
6: Is it a stand-alone
screening test or is it one of a series of screening tests? The
DNA testing that is used for screening couples prenatally to detect
cystic fibrosis in the fetus is a "stand-alone" laboratory
test. It may be proceeded
in some programs by a screening question concerning race/ethnicity that
is used to determine which couples would be offered screening.
Other programs may provide race- and ethnic-specific test
performance estimates and leave the decision about test acceptance up to
the couple. DISORDER/SETTING Question
7: If it is part of a
series of screening tests, are all tests performed in all instances
(parallel) or are some tests performed only on the basis of other
results (series)? If
a screening question about race/ethnicity is used initially then DNA
testing will be performed only on those identified as suitable
candidates. In this
instance, the DNA testing will be performed on the basis of the
preliminary screening test and, therefore, the tests are performed in
series.
|
|
Updated on August 13, 2004